ACXP Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 29.60%

Insider Buying (Last 12 Months): $74,630.92

Insider Selling (Last 12 Months): $0.00

Acurx Pharmaceuticals Insider Trading History Chart

Acurx Pharmaceuticals Share Price & Price History

^$0.46

▼ -0.0069 (-1.48%)

As of 03/13/2025 05:00 PM ET

Days: 30 | 90 | 365

Acurx Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/6/2025	David P. Luci	CEO	Buy	49,261	$1.01	$49,753.61	1,097,458
1/6/2025	Joseph C Scodari	Director	Buy	24,631	$1.01	$24,877.31	27,708
7/27/2022	Carl Sailer	Director	Buy	19,737	$3.80	$75,000.60	92,815

SEC Filings (Institutional Ownership Changes) for Acurx Pharmaceuticals (NASDAQ:ACXP)

11.53% of Acurx Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Acurx Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
1/22/2025	Prospect Financial Services LLC	329,076	$0.27M	0.1%	+11.5%	1.932%
11/16/2024	Geode Capital Management LLC	146,500	$0.28M	0.0%	+12.7%	0.902%
10/15/2024	Prospect Financial Services LLC	295,075	$0.56M	0.3%	+6.1%	1.862%
7/15/2024	Prospect Financial Services LLC	278,100	$0.63M	0.5%	+1.9%	1.756%
4/23/2024	Prospect Financial Services LLC	272,850	$0.67M	0.6%	+6.9%	1.732%
4/5/2024	NBC Securities Inc.	14,000	$34K	0.0%	N/A	0.089%
2/20/2024	Prospect Financial Services LLC	255,150	$0.98M	1.0%	N/A	1.853%
2/1/2024	Sigma Planning Corp	10,000	$38K	0.0%	N/A	0.073%
11/15/2023	Armistice Capital LLC	500,000	$0.75M	0.0%	-57.7%	3.843%
8/14/2023	One68 Global Capital LLC	13,044	$35K	0.2%	N/A	0.101%
11/14/2022	Armistice Capital LLC	1,066,000	$3.20M	0.1%	N/A	9.224%
8/12/2022	Semmax Financial Advisors Inc.	5,879	$28K	0.0%	+365.5%	0.057%
8/1/2022	Castle Wealth Management LLC	13,000	$49K	0.0%	N/A	0.127%
1/10/2022	Patriot Financial Group Insurance Agency LLC	7,000	$30K	0.0%	+75.0%	0.069%
11/15/2021	Tocqueville Asset Management L.P.	19,100	$98K	0.0%	+91.0%	0.189%
11/9/2021	BlackRock Inc.	6,515	$33K	0.0%	N/A	0.064%
8/16/2021	Tocqueville Asset Management L.P.	10,000	$64K	0.0%	N/A	0.105%

Data available starting January 2016

See Full Table

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Today's Range

Now: $0.46

$0.44

$0.46

50 Day Range

MA: $0.74

$0.45

$1.09

52 Week Range

Now: $0.46

$0.43

$3.33

Volume

114,161 shs

Average Volume

149,267 shs

Market Capitalization

$8.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Acurx Pharmaceuticals?: Acurx Pharmaceuticals' top insider investors include:
David P Luci (CEO)
Joseph C Scodari (Director)
Learn More about top insider investors at Acurx Pharmaceuticals.
Who are the major institutional investors of Acurx Pharmaceuticals?: Acurx Pharmaceuticals' top institutional shareholders include:
Prospect Financial Services LLC — 1.93%
Citadel Advisors LLC — 0.00%
Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of Acurx Pharmaceuticals stock.
Which major investors are selling Acurx Pharmaceuticals stock?: Within the last quarter, ACXP stock was sold by these institutional investors:
Citadel Advisors LLC
Which major investors are buying Acurx Pharmaceuticals stock?: During the last quarter, ACXP stock was bought by institutional investors including:
Prospect Financial Services LLC
During the last year, these company insiders have bought Acurx Pharmaceuticals stock:
David P Luci (CEO)
Joseph C Scodari (Director)
Learn More investors buying Acurx Pharmaceuticals stock.